HRP20170735T1 - Oksidirani avidin s dugim trajanjem zadržavanja u obrađenim tkivima - Google Patents
Oksidirani avidin s dugim trajanjem zadržavanja u obrađenim tkivima Download PDFInfo
- Publication number
- HRP20170735T1 HRP20170735T1 HRP20170735TT HRP20170735T HRP20170735T1 HR P20170735 T1 HRP20170735 T1 HR P20170735T1 HR P20170735T T HRP20170735T T HR P20170735TT HR P20170735 T HRP20170735 T HR P20170735T HR P20170735 T1 HRP20170735 T1 HR P20170735T1
- Authority
- HR
- Croatia
- Prior art keywords
- oxidized avidin
- avidin
- complex
- oxidized
- intended
- Prior art date
Links
- 108090001008 Avidin Proteins 0.000 title claims 18
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 238000002725 brachytherapy Methods 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000004224 pleura Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000001082 somatic cell Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000009121 systemic therapy Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000017423 tissue regeneration Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Oksidizirani avidin u kojem je najmanje jedan manozni ostatak po molekuli avidina zamijenjen ostatkom sljedeće formule
[image]
,
naznačen time što navedeni oksidizirani avidin sadrži otprilike 8 do 15 aldehidnih ostataka i ima toplinsku stabilnost koja je jednaka ili iznad 78 °C.
2. Kompleks, naznačen time što se sastoji od oksidiziranog avidina u skladu s patentnim zahtjevom 1 i biotiniliranog terapijskog sredstva.
3. Kompleks u skladu s patentnim zahtjevom 2, naznačen time što je biotinilirano terapijsko sredstvo sredstvo protiv raka.
4. Kompleks u skladu s patentnih zahtjeva 2 ili 3, naznačen time što je namijenjen upotrebi kao medikament.
5. Oksidizirani avidin u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u terapijskom liječenju, gdje se oksidizirani avidin primjenjuje na pacijentu u prvom koraku liječenja, a zatim se primjenjuje biotinilirano terapijsko sredstvo.
6. Kompleks u skladu s patentnim zahtjevom 3 ili oksidizirani avidin u skladu s patentnim zahtjevom 5, naznačen time što je namijenjen upotrebi u brahiterapije u liječenju pacijenta koji boluje od raka kao bolesti.
7. Kompleks ili oksidizirani avidin u skladu s patentnim zahtjevom 6, naznačen time što rak kao bolest je rak dojke, gušterače, pluća, poplućnice, potrbušnice, lica i vrata, mokraćnog mjehura, na mozgu, prostate, jajnika ili očiju.
8. Kompleks ili oksidizirani avidin u skladu s patentnim zahtjevom 7, naznačen time što se biotinilirano terapijsko sredstvo bira iz skupine koju čine radioizotopi, kemoterapijska sredstva, citokini, toksini i protutumorske stanice.
9. Kompleks u skladu s patentnim zahtjevom 4 ili oksidizirani avidin u skladu s patentnim zahtjevom 5, naznačen time što terapijsko sredstvo predstavljaju biotinilirane matične stanice ili somatske stanice namijenjene liječenju raka, degenerativnih ili genetičkih bolesti.
10. Oksidizirani avidin u skladu s patentnim zahtjevom 1 ili kompleks u skladu s patentnim zahtjevom 4, naznačen time što je namijenjen primjeni u regeneraciji tkiva korisnoj u liječenju autoimunih/degenerativnih/genetičkih bolesti, uključujući dijabetes, multiplu sklerozu, reumatoidni artritis, Alzheimerovu bolest, ozljedu kralježnice, Duchenneovu mišićnu distrofiju, infarkt miokarda i inzult.
11. Kompleks ili oksidizirani avidin u skladu s patentnim zahtjevom 8, naznačen time što se navedeni radioizotop bira iz skupine koju čine Fe-52, Mn-52m, Co-55, Cu-64, Ga-67, Ga-68, Tc-99m, In-111, I-123, I-125, I-131, P-32, Sc-47, Cu-67, Y-90, Pd-109, Ag-111, I-131, Pm-149, Re-186, Re-188, At-211, Pb-212, Bi-212 i Lu-177.
12. Farmaceutski pripravak, naznačen time što sadrži oksidizirani avidin ili kompleks u skladu s bilo kojim od patentnih zahtjeva 1 do 3, uz farmaceutski prihvatljivu pomoćnu tvar.
13. Komplet, naznačen time što sadrži farmaceutski pripravak u skladu s patentnim zahtjevom 12, koji sadrži oksidizirani avidin u skladu s bilo kojim od patentnih zahtjeva 1-3 u spremniku i biotinilirano terapijsko sredstvo u drugom spremniku.
14. Komplet u skladu s patentnim zahtjevom 13, naznačen time što je namijenjen adjuvantnoj intra- i perioperativnoj lokoregionalnoj i/ili sistemnoj terapiji u dva koraka, gdje su dva spremnika u obliku injekcijske štrcaljke.
15. Postupak oksidiranja avidina, naznačen time što oksidiranje obuhvaća:
a) inkubiranje avidin divljeg tipa, prethodno pomiješanog s molarnim suviškom (HABA), s 10-20 mM natrijevog perjodata, u 50-100 mM acetatnog pufera na pH ispod 6,0, u trajanju od 1-5 sati, na 4 °C ili na sobnoj temperaturi;
b) blokiranje reakcije i pročišćavanju uklanjanjem oksidacijskog sredstvoa i HABA kromatografijom, ultrafiltriranjem ili dijalizom; i
c) liofiliziranje ili formuliranje na kiselom pH.
16. Oksidizirani avidin, naznačen time što ga se može dobiti postupkom u skladu s patentnim zahtjevom 15.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113733 | 2007-08-02 | ||
| EP08157473 | 2008-06-03 | ||
| EP08775109.5A EP2185203B1 (en) | 2007-08-02 | 2008-07-16 | Oxidized avidin with high residency time in the treated tissues |
| PCT/EP2008/059260 WO2009016031A1 (en) | 2007-08-02 | 2008-07-16 | Oxidized avidin with high residency time in the treated tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170735T1 true HRP20170735T1 (hr) | 2017-07-28 |
Family
ID=39734214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170735TT HRP20170735T1 (hr) | 2007-08-02 | 2017-05-16 | Oksidirani avidin s dugim trajanjem zadržavanja u obrađenim tkivima |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8562947B2 (hr) |
| EP (1) | EP2185203B1 (hr) |
| JP (1) | JP5577248B2 (hr) |
| KR (1) | KR101544628B1 (hr) |
| CN (1) | CN101772353B (hr) |
| AR (1) | AR067771A1 (hr) |
| AU (1) | AU2008281901B2 (hr) |
| BR (1) | BRPI0815050B8 (hr) |
| CA (1) | CA2694391C (hr) |
| DK (1) | DK2185203T3 (hr) |
| EA (1) | EA017017B1 (hr) |
| ES (1) | ES2625815T3 (hr) |
| HK (1) | HK1145290A1 (hr) |
| HR (1) | HRP20170735T1 (hr) |
| HU (1) | HUE032093T2 (hr) |
| IL (1) | IL203321A (hr) |
| LT (1) | LT2185203T (hr) |
| MX (1) | MX2010001302A (hr) |
| MY (1) | MY155347A (hr) |
| NZ (1) | NZ582711A (hr) |
| PL (1) | PL2185203T3 (hr) |
| PT (1) | PT2185203T (hr) |
| SG (1) | SG183076A1 (hr) |
| SI (1) | SI2185203T1 (hr) |
| TW (1) | TWI441650B (hr) |
| WO (1) | WO2009016031A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2660320B1 (en) * | 2010-12-28 | 2017-09-27 | Japan Tobacco Inc. | Modified tamavidin |
| EA026453B1 (ru) * | 2011-08-02 | 2017-04-28 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | Применение окисленного авидина для ингаляции |
| JP2014001204A (ja) * | 2012-05-23 | 2014-01-09 | Kumamoto Univ | 腫瘍細胞選択的抗がん剤 |
| WO2014107566A1 (en) | 2013-01-04 | 2014-07-10 | Massachusetts Institute Of Technology | Surface binding of nanoparticle based drug delivery to tissue |
| WO2017003908A1 (en) | 2015-06-30 | 2017-01-05 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
| EP3458097A4 (en) * | 2016-05-19 | 2020-01-08 | University of Miami | TARGETED DELIVERY OF THERAPEUTICS AND IMAGING REAGENTS TO PANCREASCARCELLS |
| WO2020068547A1 (en) | 2018-09-25 | 2020-04-02 | Siemens Healthcare Diagnostics Inc. | Methods and compositions for removing biotin interference from assays using conjugated molecular traps |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0733066B1 (en) * | 1993-12-07 | 2003-11-19 | NeoRx Corporation | Pretargeting methods and compounds |
| US5716594A (en) * | 1994-06-06 | 1998-02-10 | The Jmde Trust | Biotin compounds for targetting tumors and sites of infection |
| US8021667B2 (en) * | 1994-11-16 | 2011-09-20 | Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Compositions for immunotherapy and uses thereof |
| WO2000027814A1 (en) * | 1998-11-10 | 2000-05-18 | Yeda Research And Development Co. Ltd. | Avidin derivatives and uses thereof |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US20040101901A1 (en) * | 2002-11-27 | 2004-05-27 | Piotr Tabaczewski | Novel lipophilic complexes for insertion of receptors into lipid membranes |
| ITRM20030196A1 (it) * | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
-
2008
- 2008-07-16 EA EA201070216A patent/EA017017B1/ru unknown
- 2008-07-16 SG SG2012054938A patent/SG183076A1/en unknown
- 2008-07-16 JP JP2010518601A patent/JP5577248B2/ja active Active
- 2008-07-16 MX MX2010001302A patent/MX2010001302A/es active IP Right Grant
- 2008-07-16 US US12/670,925 patent/US8562947B2/en active Active
- 2008-07-16 LT LTEP08775109.5T patent/LT2185203T/lt unknown
- 2008-07-16 EP EP08775109.5A patent/EP2185203B1/en active Active
- 2008-07-16 WO PCT/EP2008/059260 patent/WO2009016031A1/en active Application Filing
- 2008-07-16 PT PT87751095T patent/PT2185203T/pt unknown
- 2008-07-16 MY MYPI2010000136A patent/MY155347A/en unknown
- 2008-07-16 AU AU2008281901A patent/AU2008281901B2/en active Active
- 2008-07-16 CN CN2008801016692A patent/CN101772353B/zh active Active
- 2008-07-16 CA CA2694391A patent/CA2694391C/en active Active
- 2008-07-16 NZ NZ582711A patent/NZ582711A/en unknown
- 2008-07-16 KR KR1020107004513A patent/KR101544628B1/ko active IP Right Grant
- 2008-07-16 HU HUE08775109A patent/HUE032093T2/en unknown
- 2008-07-16 ES ES08775109.5T patent/ES2625815T3/es active Active
- 2008-07-16 BR BRPI0815050A patent/BRPI0815050B8/pt active IP Right Grant
- 2008-07-16 PL PL08775109T patent/PL2185203T3/pl unknown
- 2008-07-16 DK DK08775109.5T patent/DK2185203T3/da active
- 2008-07-16 SI SI200831808A patent/SI2185203T1/sl unknown
- 2008-07-18 TW TW097127328A patent/TWI441650B/zh active
- 2008-08-01 AR ARP080103343A patent/AR067771A1/es active IP Right Grant
-
2010
- 2010-01-14 IL IL203321A patent/IL203321A/en active IP Right Grant
- 2010-12-16 HK HK10111803.2A patent/HK1145290A1/xx unknown
-
2017
- 2017-05-16 HR HRP20170735TT patent/HRP20170735T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170735T1 (hr) | Oksidirani avidin s dugim trajanjem zadržavanja u obrađenim tkivima | |
| JP2010535166A5 (hr) | ||
| EP1372741B1 (en) | Morpholino imaging and therapy | |
| BR112016011025B1 (pt) | Polipeptídeos anticorpo com especificidade de ligação para calicreina-2 humana (hk2), composição farmacêutica que os compreende e molécula de ácido nucleico | |
| TW202102268A (zh) | Ｈｓｐ９０靶定性共軛體類及其調製劑 | |
| US10717750B2 (en) | 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents | |
| EP3936121A1 (en) | Self assembling molecules for targeted drug delivery | |
| CN116173250A (zh) | 一种基于核酸适体的靶向分子探针及其制备方法和应用 | |
| JP7309228B2 (ja) | 甲状腺髄様がん標的用組成物 | |
| EP1615668B1 (en) | A medicament for the two-step perioperative therapy of solid tumours by radioimmunotherapy | |
| JP2006524235A5 (hr) | ||
| TWI846107B (zh) | 幾丁質酶-3-類似蛋白-1中和抗體及其用途 | |
| JP2006523706A (ja) | 増幅ターゲッティングによるモルホリノイメージングおよび治療 | |
| Paganelli et al. | Therapy trials in cancer patients using an improved 3-step pretargeting approach | |
| JP4339846B2 (ja) | 腫瘍治療剤 | |
| Wunderlich et al. | 3‐O‐methyl‐6‐[123I] IODO‐L‐DOPA (OMID)—an amino acid derivative for tumour imaging with spect |